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The angiogenic, neovascular proliferative retinopathies, proliferative diabetic retinopathy (PDR), and age-dependent macular
degeneration (AMD) complicated by choroidal neovascularization (CNV), also termed exudative or “wet” AMD, are common
causes of blindness. The antidiabetic thiazolidinediones (TZDs), rosiglitazone, and troglitazone are PPARγ agonists with
demonstrable antiproliferative, and anti-inﬂammatory eﬀects, in vivo, were shown to ameliorate PDR and CNV in rodent models,
implying the potential eﬃcacy of TZDs for treating proliferative retinopathies in humans. Activation of the angiotensin II type
1 receptor (AT1-R) propagates proinﬂammatory and proliferative pathogenic determinants underlying PDR and CNV. The
antihypertensive dual AT1-R blocker (ARB), telmisartan, recently was shown to activate PPARγ and improve glucose and lipid
metabolism, and to clinically improve PDR and CNV in rodent models. Therefore, the TZDs and telmisartan, clinically approved
antidiabetic and antihypertensive drugs, respectively, may be eﬃcacious for treating and attenuating PDR and CNV humans.
Clinical trials are needed to test these possibilities.
Copyright © 2008 H. A. Pershadsingh and D. M. Moore. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Angiogenesis and neovascularization involve formation and
proliferation of new blood vessels and have a vital role
normal growth and development, such as embryogenesis,
wound healing, tissue repair [1, 2]. However, in pathological
neovascularization,angiogenesisisaberrantandunregulated
resulting in the formation of dysfunctional blood vessels
[3]. The latter occurs in proliferative diabetic retinopathy
(PDR) and choroidal neovascularization (CNV), “wet” or
exudative age-dependent macular degeneration (AMD),
wherein pathological neovascular vessels proliferate and leak
ﬂuidleading toretinaledema,subretinalandretinal/vitreous
hemorrhage, retinal detachment, and blindness. In the
United States, PDR is the most common preventable cause
of blindness in adults <50years [4], whereas CNV/AMD is
the leading cause of blindness among people of European
origin >65years [5]. Both retinopathies are progressively
destructive, leading to eventual and irreversible blindness.
PDR is a serious microvascular complication of both type 1
and type 2 diabetes [6]. Type 2 diabetes is rapidly expanding
worldwide and is estimated to reach 380 million by 2025
[7, 8]. PDR is progressive and compounded by persistent
and substandard control of hyperglycemia, and concomitant
cardiovascular risk factors, especially hypertension [9–11].
Nearly, all type 1 diabetics and >60% of type 2 diabetics have
signiﬁcant retinopathy after 20years, emphasizing the need
for more cost-eﬀective therapy [6, 10, 11]. Hyperglycemia,
advanced glycation end-products (AGEs), and hypoxia are
believed to induce pathological angiogenesis and neovascu-
larization within the retina [12]. Prevention of end-organ
damage by early and aggressive diabetes management is the
best approach to treating diabetic retinopathy (DR) [6, 12].
Visual acuity depends on a functional macula, located
at the center of the retina where cone photoreceptors are
most abundant. Exudative (wet) AMD is complicated by
CNV, involving activation and migration of macrophages,
and normally quiescent retinal pigment epithelial cells from
the choroid and invasion of defective neovascular blood
vessels into the subretinal space [13, 14]. Bleeding and2 PPAR Research
Table 1: Growth factors, cytokines, chemokines, and other proinﬂammatory mediators downregulated by PPARγ activation. PDGF-BB,
platelet-derived growth factor-BB homodimer; AP-1, activated protein-1; NF-κB = nuclear factor-κB; NFAT = nuclear factor of activated
Tl y m p h o c y t e s ;S T A T= signal transducer and activator of transcription; ICAM, intracellular adhesion molecule; VCAM, vascular cell
adhesion molecule; iNOS, inducible nitric oxide synthase. (Adapted with permission from: B. Staels, ”PPARγ and atherosclerosis.” Current
Medical Research and Opinion, vol. 21, Suppl. 1, pp. S13-S20, 2005; H. A. Pershadsingh, “Dual peroxisome proliferator-activated receptor-
alpha/gamma agonists : in the treatment of type 2 diabetes mellitus and the metabolic syndrome.” Treatments in Endocrinology, vol. 5, no.
2, pp. 89-99, 2006.)
Growth factors Cytokines Chemokines Nuclear transcription factors Other molecules
ATII IL-1β IL-8 AP-1 IFN-γ
TGF-β IL-2 MCP-1 NF-κB iNOS
ET-1 IL-6 RANTES STAT PAI-1
bFGF TNF-α NFAT MMP-2
PDGF-BB MMP-9
EGF VCAM-1
VEGF ICAM-1
E-selectin
Table 2: Growth factors, cytokines, chemokines, and other proinﬂammatory mediators upregulated by angiotensin II stimulation. ET-1,
endothelin-1; TGF-β, transforming growth factor-β; CTGF, connective tissue growth factor; bFGF, basic ﬁbroblast growth factor; PDGF-AA,
platelet-derived growth factor-AA homodimer; EGF, epidermal growth factor; VEGF, vascular endothelial cell growth factor; IL, interleukin;
GM-CSF, granulocyte-macrophage colony-stimulating factor; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemoattractant protein-
1; MIP, macrophage inﬂammatory protein; NF-κB, nuclear factor-κB; NFAT, nuclear factor of activated T lymphocytes; STAT, signal
transducer and activator of transcription; RANTES, regulated on activation, normal T-cell expressed and secreted; IFN-γ, interferon-γ;
PAI-1, plasminogen activator inhibitor type 1; AP-1, activated protein-1. (Adapted with permission from: R. E. Schmieder, K. F. Hilgers, M.
P. Schlaich, B. M. Schmidt, “Renin-angiotensin system and cardiovascular risk.” Lancet, vol. 369, no. 9568, pp. 1208-1219, 2007.)
Growth factors Cytokines Chemokines Other proinﬂammatory molecules
ET-1 IL-1β IL-8 IFN-γ
TGF-β IL-6 MCP-1 Tissue factor
CTGF IL-18 MIP-1 PAI-1
bFGF GM-CSF RANTES
PDGF-AA TNF-α
EGF
VEGF
lipid leakage from these immature vessels damage the retina
and lead to severe vision loss and blindness [14, 15].
Current therapies of AMD are limited to treating the early
stages of the disease, and include laser photocoagulation,
photodynamic therapy, surgical macular translocation, and
antiangiogenesis agents [13–16]. These invasive procedures
are expensive, require repetition, whereas pharmacologic
approaches could simplify therapy and reduce cost.
The peroxisome proliferator-activated receptor (PPAR)
class of nuclear receptors (PPARα,P P A R β/δ,a n dP P A R γ)
belongs to the nuclear receptor superfamily that include
the steroid, thyroid hormone, vitamin D, and retinoid
receptors [17, 18]. In 1995, Lehmann et al. [19] discovered
that PPARγ was the intracellular high aﬃnity receptor
for the insulin-sensitizing, antidiabetic thiazolidinediones
(TZDs), the activation of which also promotes growth arrest
of preadipocytes, diﬀerentiation, adipogenesis, and diﬀer-
entiation into mature adipocytes [20]. Ligand activation
of PPARγ also downregulates the transcription of genes
encoding inﬂammatory molecules, inﬂammatory cytokines,
growth factors, proteolytic enzymes, adhesion molecules,
chemotactic, and atherogenic factors [21–25]( Table 1).
Angiotensin II (AII) and components of the renin-
angiotensin system (RAS) are expressed in the retina [26,
27]. AII promotes retinal leukostasis by activating the
angiotensintype1receptor(AT1-R)pathwaythatpropagates
proinﬂammatory, proliferative mediators (Table 2) leading
to the development and progression of PDR [28–30]a n d
CNV [31]. By selectively blocking the AT1-R, angiotensin
receptor blockers (ARBs) or “sartans,” for example, valsartan
and telmisartan have been shown to confer neuroprotective
and anti-inﬂammatory eﬀects in animal models of retinal
angiogenesis and neovascularization [32–36]. Among the
seven approved ARBs, telmisartan and irbesartan were
recently shown to constitute a unique subset of ARBs also
capable of activating PPARγ [37–39]. Valsartan and the
remaining ARBs were inactive in the PPARγ transactivation
assay. In fact, telmisartan was shown to downregulate AT1
receptors through activation of PPARγ [40]. Telmisartan was
shown to provide therapeutic beneﬁts in rodent models of
PDR [33, 41–44] and CNV [45] but data with irbesartan is
unavailable. Therefore, telmisartan and possibly irbesartan
(data unavailable) may have enhanced eﬃcacy in treating
proliferative retinopathies. ARBs are safe and have beneﬁcialH. A. Pershadsingh and D. M. Moore 3
Table 3:Comparisonofpharmacologicalandotherrelevantpropertiesofthiazolidinedione(TZD)fullPPARγ agonistsanddualangiotensin
II type 1 receptor blocker/selective PPARγ modulator (ARB/SPPARγM).
Parameter TZDs† ARBs∗
Troglitazone Pioglitazone Rosiglitazone Telmisartan Irbesartan
Primary pharmacological target PPARγ PPARγ PPARγ AT1-R AT1-R
Type of PPARγ agonists Full PPARγ agonists Selective PPARγ modulator (SPPARγM)
Drug class (common names) Thiazolidinedione (TZDs) Angiotensin receptor blockers (ARBs)
PPARγ activation (EC50 in μM) 0.55 0.58 0.043 4.5 27
Therapeutic indication Treatment of type 2 diabetes mellitus Treatment of hypertension
Primary therapeutic mechanism Increase insulin sensitivity Lower blood pressure
Serious adverse eﬀect Fluid retention/weight gain/heart failure None None
(Black box warning)
Supplier/Pharmaceutical Co.
Sigma-Aldrich, Takeda GlaxoSmithKline, Boehringer-Ingelheim Sanoﬁ-Aventis,
St. Louis, Pharmaceuticals NC, USA Pharmaceuticals, Inc., Bridgewater,
Mo, USA Deerﬁeld, Ill, USA Ridgeﬁeld, Conn, USA NJ, USA
† Thiazolidinedione full PPARγ agonists; troglitazone was withdrawn from the market (1998) because of association with rare cases of fatal hepatic failure.
Rosiglitazone and pioglitazone have no such known association.
∗Other FDA-approved ARBs had EC50 values > 100μM( s e e[ 37, 38]). EC50 values shown were determined using the standard PPARγ-GAL4 transactivation
assays.
cardiometabolic, anti-inﬂammatory, and antiproliferative
eﬀects. Among these telmisartan and irbesartan may have
improved eﬃcacy for targeting proliferative retinopathies.
Table 3 provides relevant information on the various drugs
described herein.
2. TISSUE DISTRIBUTION PPARγ
Four PPARγ mRNA isoforms have been identiﬁed [46]
that encode two proteins, PPARγ1a n dP P A R γ2[ 47, 48].
PPARγ1 is the principal subtype expressed in diverse tissues,
whereas PPARγ2 predominates in adipose tissue [49, 50].
The PPARγ2 protein diﬀers from PPARγ1 by the presence of
30 additional amino acids [49]. Tissue-speciﬁc distribution
of isoforms and the variability of isoform ratios raise the
possibility that isoform expression might be modulated
by or reﬂect disease states in which PPARγ activation
or inactivation has a role. In humans, PPARγ is most
abundantly expressed mainly in white adipose tissue and
large intestine, and to a signiﬁcant degree in kidney, heart,
small intestine, spleen, ovary, testis, liver, bone marrow,
bladder, epithelial keratinocytes, and to a lesser extent in
skeletal muscle, pancreas, and brain [51].
2.1. PPARγ expressionintheeye
PPARγ is heterogeneously expressed in the mammalian
eye [51–53]. PPARγ was found to be most prominent in
the retinal pigmented epithelium, photoreceptor outer seg-
ments, choriocapillaris, choroidal endothelial cells, corneal
epithelium, and endothelium, and to a lesser extent, in the
intraocular muscles, retinal photoreceptor inner segments
and outer plexiform layer, and the iris [52]. Ligand-
dependent activation of PPARγ evokes potent inhibition of
corneal angiogenesis and neovascularization [53–55]. The
prominent expression of PPARγ in selected tissues of the
retina [52–54] provides the rationale for pharmacotherapeu-
tic targeting of PPARγ for treating ocular inﬂammation and
proliferative retinopathies [53–56].
2.2. ImportanceofPPARγ inproliferativeretinopathy
To determine whether endogenous PPARγ played a role in
experimental DR, Muranaka et al. [54] evaluated retinal
leukostasis and retinal (vascular) leakage in streptozotocin-
induced diabetic C57BL/6 mice deﬁcient in PPARγ expres-
sion (heterozygous genotype, PPARγ+/−) after 120days.
Retinal leukostasis and leakage were greater (205% and
191%, resp.) in the diabetic PPARγ+/− mice, compared
to diabetic wild-type (PPARγ+/+) mice. In streptozotocin-
induced diabetic Brown Norway rats, oral administration of
the TZD PPARγ ligand, rosiglitazone for 21 days (3mg/kg
body weight/day, initiated post-streptozotocin injection)
resulted in suppression of retinal leukostasis by 60.9% (P<
.05), and retinal leakage by 60.8% (P<. 05) [54]. Expres-
sion of the inﬂammatory molecule. ICAM-1 protein was
upregulated in the retina of the rosiglitazone-treated group,
though the levels of VEGF and TNF-α were unaﬀected
[54]. These ﬁndings provide strong evidence for a role of
PPARγ activity in the pathogenesis of DR and provide novel
genomic information that therapeutic targeting of PPARγ
with a known PPARγ ligand, the TZD rosiglitazone, can
attenuate the progression of PDR. Whether a similar eﬀect
may apply to the prevention or attenuation of CNV is
currently unknown and should be explored.
3. ANTIDIABETIC THIAZOLIDINEDIONES (TZDs) AND
PROLIFERATIVE RETINOPATHIES
Theinsulin-sensitizingTZDs,rosiglitazone,andpioglitazone
are approved for the treatment of type 2 diabetes. Because
they increase target tissue sensitivity to insulin without4 PPAR Research
increasing insulin secretion [57], there is no risk of hypo-
glycemia, though there is a risk ﬂuid retention in diabetic
patients, especially those with coexisting heart failure, or at
risk for developing CHF [58].
By activating PPARγ, TZDs modulate groups of genes
involved in energy metabolism [59], inﬂammation, and cel-
lular diﬀerentiation [60–64] by down-regulating the activity
of the proinﬂammatory nuclear receptors (NF-κB, AP-1,
STAT, NFAT), and inhibiting the activity and expression of
inﬂammatory cytokines (TNF-α,I L - 1 β, IL-2, IL-6), iNOS,
proteolytic enzymes (MMP-3 and MMP-9), and growth
factors (VEGF, PDGF-BB, bFGF, EGF, TGF-β)( Table 1).
Because of these broadly beneﬁcial and protective actions of
PPARγ agonists, TZDs have been under development for the
treatment of conditions beyond type 2 diabetes, including
atherosclerosis [64, 65], psoriasis [66], inﬂammatory colitis
[67], nonalcoholic steatohepatitis [68], and Alzheimer’s
disease [69]. More recently, TZDs have been found to protect
against glutamate cytotoxicity in retinal ganglia and have
antioxidant properties [70] suggesting that PPARγ agonists
could prove valuable in targeting retinal complications [71].
3.1. Therapeuticeffectsonproliferative
diabeticretinopathy(PDR)
Retinal capillaries consist of endothelial cells, basement
membrane neovascularization, and intramural pericytes
within the basement membrane which are important in
vascular development and maturation [44]. Selective loss
of pericytes from the retinal capillaries characteristically
occurs early in diabetic retinopathy (DR) [72]. Diabetic
macular edema (DME), often associated with PDR, involves
breakdown of the blood-retinal barrier and leakage of
plasma from blood vessels in the macula causing macular
edema and impaired vision [73, 74]. Resorption of the
ﬂuid from plasma leads to lipid and lipoprotein deposition
forming hard exudates [75]. In PDR, inﬂammation leads
to endothelial dysfunction, retinal vascular permeability,
vascular leakage, and adhesion of leukocytes to the retinal
vasculature(leukostasis),progressivecapillarynonperfusion,
and DME [12]. Intraretinal microvascular abnormalities and
progressive retinal ischemia lead to neovascular proliferation
within the retina, bleeding, vitreous hemorrhage, ﬁbrosis,
and retinal detachment [74–76]. Despite advancements in
ophthalmologiccareandthemanagementofbothtype1and
type 2 diabetes, PDR remains a leading cause of preventable
blindness [5–7]. Primary interventions, especially intensive
glycemic and blood pressure control, and management
of other cardiovascular risk factors are essential [6, 73–
75]. Focal laser photocoagulation remains the only surgical
option for reducing signiﬁcant visual loss in eyes with mac-
ular edema [6, 9–12]. The risk of blindness with untreated
PDR is currently greater than 50% at 5years, but can be
reduced to less than 5% with appropriate therapy [5–7]. At
present,thereisinsuﬃcientevidencefortheeﬃcacyorsafety
of pharmacological interventions, including therapy target-
ing vascular endothelial growth factor (i.e., anti-VEGF anti-
body therapy), though intravitreal glucocorticoids may be
considered when conventional treatments have failed [6, 12].
Troglitazone and rosiglitazone were shown to attenuate
VEGF-induced retinal endothelial cell proliferation, migra-
tion, tube formation, and signaling, in vitro [55] by arresting
the growth cycle of endothelial cells [62]. Local intrastromal
implantation of micropellets containing pioglitazone into
rat corneas signiﬁcantly decreased the density of VEGF-
induced angiogenesis, an accepted animal model of retinal
neovascularization [53].
Adverse conditions that contribute to macular edema
and retinal degeneration in PDR include generation of
advanced glycation end products (AGEs), local ischemia,
oxidative reactions, and hyperglycemia-induced toxicity
[72, 75, 76]. In PPARγ-expressing retinal endothelial cells,
troglitazone, and rosiglitazone inhibited VEGF-stimulated
proliferation, migration, and tube formation [55, 77]. The
eﬀects of troglitazone and rosiglitazone were also evaluated
in the oxygen-induced ischemia murine model of retinal
neovascularization, an experimental model of PDR [77].
Although the model lacks speciﬁc metabolic abnormalities
found in diabetes, it isolates the VEGF-driven process in
which neovascularization is stimulated by increased VEGF
expression in the inner retina [77]. Both troglitazone
and rosiglitazone decreased the number of microvascular
tufts induced on the retinal surface, suggesting inhibition
of an early aspect of neovascularization. The inhibitory
eﬀects were dose-dependent (IC50   5μmo1/L) [77].
These ﬁndings support the proposal that TZDs may have
beneﬁcial eﬀects by reducing or delaying the onset of PDR
in diabetic patients. Prospective clinical trials are required to
demonstrate clinical eﬃcacy.
3.2. Therapeuticeffectsonchoroidal
neovascularization(CNV)
AMD complicated with CNV involves angiogenesis and
neovascularization in the choroid with hemorrhage in the
subretinal space, ﬂuid accumulation beneath the photore-
ceptors within the fovea, and neural cell death in the outer
retina [13–16]. CNV is present with vascular inﬂammation,
unbridled vascular proliferation, aberrant epithelial and
endothelial cell migration, and inappropriate production of
proinﬂammatory cytokines, inducible nitric oxide synthase,
growth factors, proteolytic enzymes, adhesion molecules,
chemotactic factors, atherogenic, and other mediators
that propagate defective blood vessel proliferation [5, 13–
16, 78]. Elevated blood pressure, serum lipids, smoking,
and insulin resistance also have an etiological role in CNV
development [78]. Therefore, control of cardiometabolic
risk factors is important in palliative management of
CNV [79, 80]. Recently, therapy for early exudative
AMD has been directed toward intravitreal injection of
VEGF-directed antibodies or fragments thereof [14–16].
However, excessive cost ($1,950/dose) is a major issue
[http://www.globalinsight.com/SDA/SDADetail6273.htm].
Monthly treatments are diﬃcult for patients to tolerate, and
the risk of serious adverse eﬀects increases over time [16].
On the other hand, synthetic, nonpeptide PPARγ agonists
[81, 82] are straightforward to synthesize, inexpensive to
formulate.H. A. Pershadsingh and D. M. Moore 5
CNV comprises the underlying pathology of exudative
AMD, principally involving the subretinal vasculature and
choriocapillaris, leading to capillary closure and retinal
ischemia, angiogenesis, retinal neovascularization, bleeding
into the vitreous, retinal detachment and degeneration,
and eventually vision loss [13–16]. PPARγ is expressed
in the choriocapillaris, choroidal endothelial cells, retinal
endothelial cells, and retinal pigmented epithelium [52, 83].
VEGF is a potent inducer of retinal [13–16] angiogenesis
and neovascularization. In their landmark study, Murata
et al. [83] demonstrated the expression of PPARγ1i n
human retinal pigment epithelial (RPE) cells and bovine
choroidal endothelial cells (CECs), and that application
of the TZDs troglitazone or rosiglitazone (0.1–20μmol/L)
inhibited VEGF-induced proliferation and migration of RPE
and CEC cells, and neovascularization [83]. Moreover, in the
eyes of rat and cynomolgus monkeys in which CNV was
induced by laser photocoagulation, intravitreal injection of
troglitazone markedly inhibited CNV compared to control
eyes (P<. 001). The treated lesions showed signiﬁcantly
less ﬂuorescein leakage and were histologically thinner in
troglitazone-treated animals, without adverse eﬀects in the
adjacentretinaorincontroleyes[83].Theseﬁndingssuggest
thatpharmacologicalactivationofPPARγ byTZDsappearto
have a palliative or therapeutic eﬀect on experimental CNV.
Again, clinical trials are required to demonstrate eﬃcacy in
the clinical setting.
3.3. AdverseeffectsofTZDs:ﬂuidretention
andmacularedema
Pioglitazone and rosiglitazone are generally safe though, in
type 2 diabetic patients, there is a risk of weight gain (1–3kg)
and ﬂuid retention [58]. The incidence of peripheral edema
is greater in those concurrently taking exogenous insulin,
increasing from 3.0–7.5% to 14.7–15.3% [58]. The edema
may be related to TZD-induced vasodilation, increased
plasma volume secondary to renal sodium reabsorption,
and reﬂex sympathetic activation [58]. The association of
rosiglitazone treatment with development of macular edema
has been reported [84]. In a case review of 11 patients
who developed peripheral and macular edema, while on
the TZD therapy [85] 8 patients experienced resolution of
macular edema with improved vision, without laser treat-
ment, 3months to 2years after TZD cessation. Therefore,
DMEshouldbeconsideredintype2diabeticpatientstreated
with a TZD, especially those with peripheral edema, or other
symptoms or risk factors of CHF, or concurrently taking
exogenous insulin or nitrates. Drug cessation usually results
in rapid resolution of both peripheral and macular edema
[85].
4. ANTIHYPERTENSIVE ANGIOTENSIN RECEPTOR
BLOCKERS (ARBs) THAT ACTIVATE PPARγ
In their search for PPARγ agonists that lack the adverse
eﬀects of TZDs, Benson et al. [37] screened the active
forms of all currently available antihypertensive “sartans”
(ARBs): losartan, valsartan eprosartan, irbesartan, candesar-
tan, telmisartan, and olmesartan, using the standard GAL-
4 cell-based PPARγ transactivation assay. Only telmisartan
and irbesartan [37, 38] activated PPARγ and promoted
adipogenesis, intracellular lipid accumulation and diﬀeren-
tiation of preadipocyte ﬁbroblasts into mature adipocytes,
in vitro, hallmark properties of PPARγ agonists [19]. The
EC50 values for transactivation of PPARγ by telmisartan
and irbesartan were 4.5μmol/L and 27μmol/L, respectively
[37–39]( Table 3). Although the PPARγ transactivation assay
may not recapitulate conditions in vivo, based on phar-
macokinetic considerations, concentrations of these ARBs
required to activate PPARγ invivoareachievablebystandard
dosing [86, 87]. By functioning as partial PPARγ agonists
this unique subset of ARBs may provide added end-organ
beneﬁts in certain patient populations such patients with
the metabolic syndrome [87] and other cardiometabolic risk
factors, including atherosclerosis, atherogenesis, and may
have palliative eﬀects on proliferative retinopathies.
ARBs bear an acidic group (tetrazole or carboxyl group)
at the ortho position on the terminal benzene ring of the
biphenyl moiety, which is essential for AT1 receptor binding.
Telmisartan bears a carboxyl and irbesartan, a tetrazole
[87, 88] .T h ea c t i v ef o r m so fa l lo t h e rA R B sh a v et w o
acidic groups at opposite molecular poles. This second
acidic group limits accessibility, and hinders binding to
the hydrophobic region of the PPARγ receptor [87, 88].
Therefore, among currently available ARBs, the molecular
dipole appears to be an important structure-functional
determinant of ligand binding to the PPARγ receptor [87].
Compared to all other ARBs, telmisartan has a uniquely long
elimination half-life (24hours), and the largest volume of
distribution (500L, and >10-fold in excess of other ARBs)
which greatly increases central bioavailability upon oral
dosing [86]. Furthermore, telmisartan has been shown to
have signiﬁcant anti-inﬂammatory and antioxidant activity,
which may enhance its eﬀectiveness in attenuating the
progression of proliferative retinopathies [89–91].
4.1. FullversuspartialPPARγ agonists
The PPARγ receptor is composed of ﬁve diﬀerent domains,
an N-terminal region or domain A/B, a DNA binding
domain C (DBD), a hinge region (domain D), a ligand
binding domain E (LBD), and a domain F [81, 92, 93]. The
A/B domain contains an activation function-1 (AF-1) that
operatesinabsenceofligand.TheDBDconfersDNAbinding
speciﬁcity. PPARγ controls gene expression by binding
to speciﬁc DNA sequences or peroxisome proliferation-
responsive elements (PPREs) in the regulatory region of
PPAR-responsive genes. The large LBD (∼1300 ˚ A
3)a l l o w s
thereceptortointeractwithabroadrangeofstructurallydis-
tinct natural and synthetic ligands [81, 92, 93]. The receptor
proteincontains13helices,andtheactivationfunction,AF-2
helix located in the C terminus of the LBD is intimately inte-
grated with the receptor’s coactivator binding domain [81].
Ligand-dependent stabilization is required for activation of
the downstream transcriptional machinery [81, 92, 93].
Thiazolidinedione full agonists (TZDfa), for example,
rosiglitazone and pioglitazone permit certain coactivators to6 PPAR Research
S342
Telmisartan
GW0072
Figure 1: Telmisartan (blue) superimposed on the co-crystal struc-
ture of GW0072 (red) bound within the PPARγ-LBD. Telmisartan
and GW0072 are Van der Waals space-ﬁlling representations, and
the protein backbone by the yellow ribbon. Formation of hydrogen
bonds and interactions between both ligands and the amide proton
of Ser342 contribute toward stabilization of the partial agonists
within the PPARγ-LBD. (Kindly provided by Dr. P.V. Desai &
Professor M.A. Avery, Department of Medicinal Chemistry, University
of Mississippi, USA.)
interact with the PPAR-LBD in an agonist-dependent man-
ner and are oriented by a “charge clamp” formed by residues
within helix 3 and the AF-2 arm of helix 12 in the LBD [45,
93]. Based on protease digest patterns and crystallographic
ﬁndings, the PPARγ non-TZD partial agonist (nTZDpa)
[94]andPP ARγ partialagonist/antagonist,GW0072[95]ar e
mainly stabilized by hydrophobic interactions with helixes
H3 and H7.
The antihypertensive ARBs telmisartan and irbesartan
have been shown to function as partial PPARγ agonists,
similar to the previously identiﬁed nTZDpa [94]. Based on
molecular motifs, telmisartan appears to occupy a region in
proximity with helix 3, with key interactions between the
carboxylic acid group of the ligand and Ser342 near the
entrance of the PPARγ pocket [37]( Figure 1). Telmisartan
and irbesartan appear to cause an alteration in the confor-
mation of these helixes similar to that induced by nTZDpa
[37, 39], promoting diﬀerences in receptor activation and
target gene expression that confer a low adipogenic potential
compared with full agonists (TZDfa) like rosiglitazone and
pioglitazone, which are known to have a high adipogenic
potential and promote weight gain [58, 81, 94]. Diﬀerential
binding motifs reﬂecting full versus partial PPARγ agonism
are illustrated in Figure 2.
Several coactivators, including CREB-binding protein
complex, CBP/p300, steroid receptor coactivator (SRC)-
1, nuclear receptor corepressor (NcoR), DRIP204, PPAR
binding protein (PBP)/TRAP220, and PPARγ coactivator-1
(PGC-1), among others, interface functionally between the
SPPARM model
Diﬀerent PPARγ agonists induce distinct receptor conformations
Ligand 2
Ligand 1 Ligand 3
PPARγ
receptor
Ligand 1 Ligand 3
Ligand 2
Diﬀerential interactions with cofactors,
histones, and other transcription factors, etc.
Diﬀerential gene activation/repression
Ligand 1
Ligand 2
Ligand 3
Figure 2:SelectivePPARγ modulator(SPPARγM)modelofPPARγ
ligandaction.PPARγ isamultivalentreceptorwhoseligandbinding
domain can accommodate diﬀerent PPARγ ligands. Ligands 1,
2, or 3 (e.g., full agonist, partial agonist, or SPPARγM) are
capable of inducing distinct receptor combinations leading to
selective gene expression. Each ligand-receptor complex assumes
a somewhat diﬀerent three-dimensional conformation, leading
to unique and diﬀerential interactions with cofactors, histones
(acetylases/deacetylases), and other transcription factors. Conse-
quently,eachPPARγ ligand-receptorcomplexleadstoadiﬀerential,
but overlapping, pattern of gene expression. Thus, each ligand
will activate, or repress multiple genes leading to diﬀerential
overlapping expression of diﬀerent sets of genes. (Adapted with
permission from: J. M. Olefsky, “Treatment of insulin resistance
with peroxisome proliferator-activated receptor gamma agonists.”
Journal of Clinical Investigation, vol. 106, no. 4, pp. 467-472,
2000); H. A. Pershadsingh, “Treating the metabolic syndrome
using angiotensin receptor antagonists that selectively modulate
peroxisome proliferator-activated receptor-gamma.” International
Journal of Biochemistry and Cellular Biology, vol. 38, nos 5-6, pp.
766-781, 2006.)
nuclear receptor and the transcription initiation machinery
in ways not well understood [94]. Diﬀerential ligand-
induced initiation of transcription is the consequence of
diﬀerential recruitment and release of selective coactiva-
tors and corepressors [96]( Figure 3). For example, NcoR
a silencing mediator when bound to PPARγ suppresses
adipogenesis in the absence of ligand. Activation by TZDfa
ligandscausesreleaseofNcoRandrecruitmentofthenuclear
receptor coactivator complex, NcoA/SRC-1 which promotes
adipogenesis and lipid storage [94].H. A. Pershadsingh and D. M. Moore 7
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Figure 3: Schematic diagram of the mechanisms of PPARγ action. In the unliganded state (top), the PPARγ receptor exists as a heterodimer
with the RXR nuclear receptor and the heterodimer is located on a PPAR response element (PPRE) of a target gene. The unliganded receptor
heterodimercomplexisassociatedwithamulticomponentcorepressorcomplex,whichphysicallyinteractswiththePPARγ receptorthrough
silencing mediator for retinoid and thyroid hormone receptors (SMRT). The corepressor complex contains histone deacetylase (HDAC)
activity, and the deacetylated state of histone inhibits transcription. After PPARγ ligand binding, the corepressor complex is dismissed, and
a coactivator complex is recruited to the heterodimer PPARγ receptor (bottom). The coactivator complex contains histone acetylase activity,
leading to chromatin remodeling, facilitating active transcription. (Adapted with permission from: J. M. Olefsky, “Treatment of insulin
resistance with peroxisome proliferator-activated receptor gamma agonists.” Journal of Clinical Investigation, vol. 106, no. 4, pp. 467-472,
2000); C. K. Glass, M. G. Rosenfeld, “The coregulator exchange in transcriptional functions of nuclear receptors”. Genes & Development,vol.
14, no. 2, pp. 121-141, 2000.)
Demonstration of direct interaction between telmisartan
or irbesartan with PPARγ protein, by analyzing migration
patternsofligand-PPARγ proteinfragmentsintrypsindiges-
tion experiments, indicated that both ARBs downregulated
PPARγ mRNA and protein expression in 3T3-L1 human
adipocytes,aknownpropertyofPPARγligandsinadipocytes
[39]. In fact, both telmisartan and irbesartan caused release
of NCoR and recruitment of NCoA/DRIP205 to PPARγ in
a concentration-dependent manner [39]. The transcription
intermediary factor 2 (TIF-2), an adipogenic coactivator
implicated in PPARγ-mediated lipid uptake and storage,
which increased the transcriptional activity of PPARγ,w a s
potentiated by pioglitazone but not by the ARBs [39]. More-
over, irbesartan and telmisartan also induced PPARγ activity
in an AT1R-deﬁcient cell model (PC12W), demonstrating
that their eﬀects on PPARγ activity were independent of
their AT1-R blocking actions [38]. These data demonstrate
the functional relevance of selective cofactor docking by
the ARBs, and compared to pioglitazone, identify telmisar-
tan and irbesartan as unique selective PPARγ modulators
(SPPARγMs) that can retain the metabolic eﬃcacy of PPARγ
activation, while reducing adverse eﬀects, in parallel AT1-
Rb l o c k a d e[ 37–39, 88]. Therefore, as dual ARB/SPPARγM
ligands, telmisartan and irbesartan have important dif-
ferential eﬀects on PPARγ-dependent regulation of gene
transcription, without the limitations of ﬂuid retention and
weight gain, providing improved therapeutic eﬃcacy by
combining potent antihypertensive, antidysmetabolic, anti-8 PPAR Research
inﬂammatory, and antiproliferative actions in the treatment
of the proliferative retinopathies.
4.2. Expressionoftherenin-angiotensin
systemintheeye
The RAS evolved to maintain volume homeostasis and blood
pressure through vasoconstriction, sympathetic activation,
and salt and water retention [97]. AII binds and activates
two primary receptors, AT1-R, and AT2-R. In adult humans,
activation of the AT1-R dominates in pathological states,
leading to hypertension, atherosclerosis, cardiac failure,
end-organ demise (e.g., nephropathy), and proliferative
retinopathies. AT2-R activation generally has beneﬁcial
eﬀects, counterbalancing the actions propagated through
AT1-R. ARBs selectively block AT1-R, leaving AII to interact
with the relatively beneﬁcial AT2-R. AII is generated in car-
diovascular, adipose, kidney, adrenal tissue, and the retina;
and through AT1-R activation promotes cell proliferation,
migration, inﬂammation, atherogenesis, and extracellular
matrix formation [97].
AII and genes enconding angiotensinogen, renin, and
angiotensin converting enzyme (ACE) have been identiﬁed
in the human neural retina [98]. Prorenin and renin have
been identiﬁed in diabetic and nondiabetic vitreous, and
intravitreal prorenin is increased in PDR [99]. Angiotensin
I and AII were found to be present in ocular ﬂuids of
diabetic and nondiabetic patients [100]. AII and VEGF
have been identiﬁed in the vitreous ﬂuid of patients
with PDR [101], and AT1 and AT2 were identiﬁed in
the neural retina [102]. Furthermore, AT1 and AT2, AII,
and its bioactive metabolite Ang-(1–7) were identiﬁed in
blood vessels, pericytes, and neural (M¨ uller) cells suggesting
that these glial cells are able to produce and process AII
[102]. Thus, AII signaling via the AT1 pathway within
the retina may mediate autoregulation of neurovascular
activity, and the onset and severity of retino-vascular disease
[103].
4.3. PathophysiologicalroleofAT1activationin
proliferativeretinopathies
AT1 activation participates in the pathogenesis of PDR,
involving inﬂammation, oxidative stress, cell hypertro-
phy and proliferation, angiogenesis, and ﬁbrosis [101,
103]. The RAS is upregulated concomitant with hypoxia-
induced retinal angiogenesis [102–104] and is linked to
AII-mediated induction of inﬂammatory mediators and
growth factors, including VEGF and PDGF [103–106].
AT1 blockade with candesartan inhibited pathological
retinopathy in spontaneously diabetic Torii rats by reduc-
ing the accumulation of the advanced glycation end-
product (AGE) pentosidine [34]. AGEs contribute to vas-
cular dysfunction by increasing the activity of VEGF and
reactive oxygen species [34] .T r e a t m e n tw i t hc a n d e s a r t a n
reduced the accumulation pentosidine and VEGF gene
expression in the diabetic rat retina [34]. AT1-R, AT2-
R, and AII were shown to be expressed in the vascular
endothelium of surgical samples from human CNV tissues
and chorioretinal tissues from mice in which CNV was
laser-induced [40]. Therefore, the retinal RAS appears to
have an important pathophysiological role in proliferative
retinopathies.
4.4. Therapeuticeffectsoftelmisartanon
PDRandCNV
AII is among the most potent vasopressive hormones known
and contributes to the development of leukostasis in early
diabetes [29]. Hypertension increases retinal inﬂammation
and exacerbates oxidative stress in experimental DR
[34, 107], and in diabetic hypertensive rats, prevention
of hypertension abrogaItes retinal inﬂammation and
leukostasis in early DR [108]. Therefore, RAS blockade by
the dual ARB/PPARγ agonists, telmisartan or irbesartan,
may have enhanced eﬀects for abrogating inﬂammatory and
other pathological events that contribute to or exacerbate
PDR and CNV/AMD. In clinical studies, reduction of
hypertension by any means reduces the risk of development
and the progression of DR [109]. ARBs are widely used
antihypertensive agents clinically.
Induction of diabetes by streptozotocin injection in
C57BL/6 mice caused signiﬁcant leukostasis and increased
r e t i n a le x p r e s s i o na n dp r o d u c t i o no fA I I ,A T 1 - R ,a n dA T 2 - R
[30]. Intraperitoneal administration of telmisartan inhibited
diabetes and glucose-induced retinal expression of ICAM-1
and VEGF, and upregulation of ICAM-1 and MCP-1, via
inhibition of nuclear translocation of NF-κB[ 33]. There
have been no reports on the eﬀects of irbesartan on PDR or
CNV/AMD.
In the laser-induced mouse model of CNV, new vessels
from the choroid invade the subretinal space after pho-
tocoagulation, reﬂecting the choroidal inﬂammation and
neovascularization seen in human exudative AMD. Based
ar e c e n ts u g g e s t i o n[ 110], Nagai et al. [45] evaluated and
compared the eﬀects of telmisartan with valsartan, an ARB
lacking signiﬁcant PPARγ activity [38, 39], and suitable con-
trol to evaluate the role of telmisartan PPARγ activity. Both
ARBs have identical aﬃnities for the AT1-R (∼10nmo1/L)
[97]. Telmisartan (5mg/kg, i.p.) or valsartan (10mg/kg, i.p.)
signiﬁcantly suppressed CNV in mice [45]. Simultaneous
administration of the selective PPARγ antagonist GW9662,
partially (22%) but signiﬁcantly reversed the suppression
of CNV in the group receiving telmisartan but not the
group receiving valsartan [45], indicating separate beneﬁcial
contributions via AT1 blockade and PPARγ activation,
respectively [45]. Using GW9662, similar ﬁndings were
obtained identifying participation of PPARγ in the suppres-
sive eﬀect of telmisartan on the inﬂammatory mediators,
ICAM-1, MCP-1, VEGFR-1 in b-End3 vascular endothelial
cells,andVEGFandinRAW264.7macrophages,unrelatedto
AT1 blockade [45].Theseﬁndingsconﬁrmthatthebeneﬁcial
eﬀects of telmisartan are derived from a combination of AT1
blockade and PPARγ activation. Theinhibitory eﬀectsofval-
sartanwereinsensitivetothepresenceofGW9662.Thisisthe
ﬁrst known demonstration of PPARγ-dependent inhibitory
actions of a non-TZD PPARγ agonist on CNV. There have
been no reports on the eﬀects of irbesartan on PDR or CNV.H. A. Pershadsingh and D. M. Moore 9
4.5. TherapeuticpotentialofdualARB/SPPARγMs
Reduction in the cardiometabolic risk proﬁle by lowering
high blood pressure, improving insulin sensitivity, normal-
izing the lipid proﬁle, and inhibiting inﬂammatory pathways
are known to impede the pathological evolution of prolifera-
tive retinopathies. The dual ARB/SPPARγM ligands, telmis-
artan has been shown to be eﬀective in this regard in the
rodent model, though irbesartan has yet to be tested experi-
mentally. PPARγ activation has beneﬁcial eﬀects by lowering
hyperglycemia and improving the metabolic proﬁle in
individualswithtype2diabetesandthemetabolicsyndrome.
The fact that both AT1-R blockade and PPARγ activation
by telmisartan had independent synergistic eﬀects in the
murine model of laser-induced CNV is an important ﬁnding
[40]. It would be useful to test whether irbesartan has eﬀects
similar to those of telmisartan in animal models of PDR and
CNV/AMD [28, 31–34, 40],as both ARBssimilarly attenuate
inﬂammation, proliferation, and improve the metabolic syn-
drome [111, 112]. Also, unlike TZDs, telmisartan (but not
valsartan) increases caloric expenditure and protects against
weight gain and hepatic steatosis [113]. With its high lipid
solubility, large volume of distribution, and other favorable
pharmacokinetic properties [86–88], telmisartan may be
eﬀective when administered orally. If oral delivery proves
therapeutically ineﬀective, the drug may be formulated for
administration via implant or transscleral application for
local delivery to the posterior segment [114–116].
5. CONCLUDING REMARKS
Hypertension, insulin resistance, dyslipidemia, and risk for
atherosclerosis and atherogenesis, all components of the
metabolicsyndrome,comprisesigniﬁcantepidemiologicrisk
factors for neovascular, proliferative retinopathies [6, 9, 12,
117, 118]. Photodynamic and anti-VEGF therapy, current
treatments for CNV/AMD are cost-intensive. Treatments for
PDR are limited to surgical options in advanced disease
when the visual function is irreversibly aﬀected [3–6, 14–
16]. Therefore, alternative, low cost, prophylactic and/or
palliativepharmacotherapeuticapproachesareattractiveand
desirable. The currently approved antidiabetic TZD, rosigli-
tazone (a full PPARγ agonist), and the antihypertensive
ARB, telmisartan (a partial PPARγ agonist) have both shown
promise in animal models of proliferative retinopathies. The
potentialeﬃcaciesofirbesartaninproliferativeretinopathies
remain to be determined. Administration of TZDs may,
in patients with AMD, slow the progression to CNV, and
in patients with diabetic retinopathy attenuate the progress
to PDR, provided that: (1) their risk of macular edema is
low, (2) they lack symptoms of CHF or cardiomyopathy,
and (3) are not taking insulin or nitrates. The eﬃcacy and
safety limitations of the TZDs are well understood [119–
123] and their use would require careful beneﬁt-to-risk
analysis. Because these drugs have been in use clinically for
a decade, well-designed retrospective analyses in carefully
selected patient populations may reveal useful information
regarding their clinical potential.
Several SPPARγMs currently which are under develop-
ment for treating type 2 diabetes [124] could be screened in
animalmodelsofPDRandCNVtodeterminetheirpotential
eﬃcacy for treating proliferative retinopathies. Long-term,
prospective clinical trials are needed to demonstrate the
eﬃcacy of currently approved TZDs and ARBs (Table 3).
Notably, three large prospective phase III trials are underway
to evaluate the eﬀect of the ARB, candesartan on retinopathy
in normotensive type 1 and type 2 diabetes patients, the dia-
betic REtinopathy candesartan trials (DIRECTs) Programme
[125]; estimated study completion date: June 2008. These
studies will provide important insight into the potential
eﬃcacy of ARBs in general in the treatment of DR. With
their capacity for activating PPARγ and improving the
metabolic proﬁle, the clinical eﬃcacy of telmisartan and
possibly irbesartan could be evaluated in patients at risk for
developing PDR and CNV, especially those with deﬁciencies
in carbohydrate and lipid metabolism. Moreover, with their
unique structure/activity proﬁle, these compounds may
provide a drug discovery platform for designing therapeutic
agents for treating proliferative retinopathies.
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